肝切除术后急性肾损伤患者连续性肾脏替代治疗中局部枸橼酸抗凝的安全性与疗效
该单中心回顾性分析纳入2013年1月19日至2018年1月19日肝切除术后发生AKI并接受CRRT的患者67例,分为无抗凝组11例、低分子肝素抗凝组25例和局部枸橼酸抗凝组31例。局部枸橼酸抗凝组ICU住院时间显著短于低分子肝素抗凝组和无抗凝组。局部枸橼酸抗凝组和低分子肝素抗凝组CRRT后血肌酐、胱抑素C和乳酸均较治疗前显著下降。局部枸橼酸抗凝组滤器使用时间和滤器数量优于其他两组,出血和频繁滤器凝血发生率显著低于其他两组,首次滤器存活时间显著长于其他两组。作者认为局部枸橼酸抗凝在肝切除术后AKI患者CRRT中安全有效。
要点
- 局部枸橼酸抗凝组ICU住院时间8.16±2.24天,显著短于低分子肝素抗凝组10.48±5.11天和无抗凝组13.29±6.64天(均P<0.05)。
- 局部枸橼酸抗凝组滤器使用时间60.52±8.82小时,长于低分子肝素抗凝组31.04±7.03小时和无抗凝组13.73±6.26小时(F=183.412,P<0.001)。
- 局部枸橼酸抗凝组出血发生0例,低于低分子肝素抗凝组4例和无抗凝组7例(χ²=23.961,P<0.001)。
- 局部枸橼酸抗凝组频繁滤器凝血发生1例,低于低分子肝素抗凝组10例和无抗凝组11例(χ²=35.413,P<0.001)。
- Kaplan-Meier分析显示局部枸橼酸抗凝组首次滤器存活时间显著长于低分子肝素抗凝组和无抗凝组(χ²=139.45,P<0.05)。
适用人群与场景
- 肝切除术后发生急性肾损伤并接受连续性肾脏替代治疗的患者,来自外科重症监护病房。
研究设计与关键结果
- 单中心回顾性分析,纳入2013年1月19日至2018年1月19日肝切除术后AKI行CRRT患者67例,分为无抗凝组11例、低分子肝素抗凝组25例、局部枸橼酸抗凝组31例。
- 三组性别、年龄、基础疾病、病因(肿瘤)、Child-Pugh分期(A或B)、CT血管造影、基础肾功能(血肌酐、胱抑素C)、美国麻醉医师协会分级、手术方式、术中出血量、输血、血压、低血压持续时间及术后循环衰竭、肝功能不全和脓毒症无显著差异。
- 局部枸橼酸抗凝组ICU住院时间8.16±2.24天,显著短于低分子肝素抗凝组10.48±5.11天和无抗凝组13.29±6.64天(均P<0.05)。
- 局部枸橼酸抗凝组和低分子肝素抗凝组CRRT后血肌酐、胱抑素C和乳酸均较治疗前显著下降(均P<0.05):血肌酐(μmol/L)局部枸橼酸抗凝组89.02±21.90 vs 248.30±55.32、低分子肝素抗凝组105.10±49.00 vs 270.10±156.00;胱抑素C(mg/L)局部枸橼酸抗凝组2.18±0.95 vs 2.94±1.26、低分子肝素抗凝组2.26±0.76 vs 3.07±0.90;乳酸(mmol/L)局部枸橼酸抗凝组2.21±1.46 vs 3.62±1.73、低分子肝素抗凝组2.37±1.24 vs 4.03±1.69。
- 低分子肝素抗凝组和无抗凝组CRRT后血红蛋白、血小板计数和活化部分凝血活酶时间较治疗前有显著变化(均P<0.05):血红蛋白(g/L)低分子肝素抗凝组85.4±5.1 vs 99.6±23.6、无抗凝组80.0±7.6 vs 101.4±7.8;血小板计数(×10⁹/L)低分子肝素抗凝组27.60±8.22 vs 62.04±16.49、无抗凝组21.36±3.91 vs 61.45±17.69;活化部分凝血活酶时间(s)低分子肝素抗凝组63.07±10.25 vs 41.52±3.65、无抗凝组49.56±5.77 vs 41.09±3.45。
- 无抗凝组CRRT后胱抑素C和凝血酶原时间较其他组显著升高:胱抑素C(mg/L)3.59±0.64 vs 2.29±0.51,凝血酶原时间(s)26.41±2.43 vs 23.64±1.92(均P<0.05)。
- 滤器使用时间(小时)局部枸橼酸抗凝组60.52±8.82、低分子肝素抗凝组31.04±7.03、无抗凝组13.73±6.26,三组差异有统计学意义(F=183.412,P<0.001);治疗期间滤器数量(个)局部枸橼酸抗凝组2.03±0.60、低分子肝素抗凝组3.12±0.73、无抗凝组4.64±1.29,三组差异有统计学意义(F=45.933,P<0.001)。
- 局部枸橼酸抗凝组出血发生0例,低于低分子肝素抗凝组4例和无抗凝组7例(χ²=23.961,P<0.001);频繁滤器凝血发生1例,低于低分子肝素抗凝组10例和无抗凝组11例(χ²=35.413,P<0.001)。Kaplan-Meier分析显示局部枸橼酸抗凝组首次滤器存活时间显著长于低分子肝素抗凝组和无抗凝组(χ²=139.45,P<0.05)。
证据类型、等级与局限
- 证据类型:单中心回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,肝切除术后AKI患者行CRRT时应用局部枸橼酸抗凝安全有效,可显著延长滤器寿命并降低出血风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the clinical effect and safety of regional citrate anticoagulation (RCA) in continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) after hepatectomy.
METHODS: A retrospective analysis of the clinical data of all patients with AKI after hepatectomy for CRRT admitted to surgical intensive care unit (ICU) of the First Affiliated Hospital of Xi'an Jiaotong University from January 19th, 2013 to January 19th, 2018 was performed. According to the different anticoagulants, the patients were divided into no anticoagulant group (NA group), low molecular heparin anticoagulation (LMHA) group and RCA group. The general data of patients during the perioperative period; renal function, the internal environment, electrolyte and blood coagulation function before and after CRRT; the filter time, the number of filters and adverse events (bleeding, frequent filter blood coagulation, metabolic alkalosis, metabolic acidosis, hypocalcemia, citrate accumulation, etc.) during CRRT were collected. Kaplan-Meier survival curve was used to analyze the life span of the first filter during different anticoagulation.
RESULTS: A total of 67 cases were included in this study, including 11 in the NA group, 25 in the LMHA group and 31 in the RCA group. There was no significant difference in gender, age, underlying disease, etiology (tumor), Child-Pugh stage (A or B), CT angiography (CTA), basic renal function [serum creatinine (SCr), cystatin C (Cys C)], the American Society of Anesthesiologists (ASA) stage; surgical approach; intraoperative bleeding volume, blood transfusion, blood pressure, time of duration of low blood pressure; and postoperative circulatory failure, hepatic insufficiency and sepsis among three groups. However, the length of ICU stay in RCA group was significantly less than the LMHA group and NA group (days: 8.16±2.24 vs. 10.48±5.11, 13.29±6.64, both P < 0.05). Compared with before CRRT, the levels of SCr, Cys C and Lac were significantly decreased in RCA group and LMHA group after CRRT [SCr (μmol/L): 89.02±21.90 vs. 248.30±55.32, 105.10±49.00 vs. 270.10±156.00; Cys C (mg/L): 2.18±0.95 vs. 2.94±1.26, 2.26±0.76 vs. 3.07±0.90; Lac (mmol/L): 2.21±1.46 vs. 3.62±1.73, 2.37±1.24 vs. 4.03±1.69, all P < 0.05]; in addition, LMHA group and NA group had significant effects on hemoglobin (Hb), platelet count (PLT) and activated partial thromboplastin time (APTT) after CRRT [Hb (g/L): 85.4±5.1 vs. 99.6±23.6, 80.0±7.6 vs. 101.4±7.8; PLT (×109/L): 27.60±8.22 vs. 62.04±16.49, 21.36±3.91 vs. 61.45±17.69; APTT (s): 63.07±10.25 vs. 41.52±3.65, 49.56±5.77 vs. 41.09±3.45, all P < 0.05]; at the same time, Cys C level and prothrombin time (PT) in the NA group after CRRT treatment were significantly increased compared with the others [Cys C (mg/L): 3.59±0.64 vs. 2.29±0.51, PT (s): 26.41±2.43 vs. 23.64±1.92 , both P < 0.05]. Finally, the time of filters (hours: 60.52±8.82, 31.04±7.03, 13.73±6.26, F = 183.412, P < 0.001) and the number of filter during treatment (number: 2.03±0.60, 3.12±0.73, 4.64±1.29, F = 45.933, P < 0.001) in the RCA group, LMHA group and NA group had statistically significant difference. Meanwhile, the incidence of adverse events such as bleeding (0 vs. 4, 7, χ 2 = 23.961, P < 0.001) and frequent filter coagulation (1 vs. 10, 11, χ 2 = 35.413, P < 0.001) in RCA group was significantly lower than that in LMHA group and NA group. Kaplan-Meier survival analysis showed that the life time of the first filter in RCA group was significantly longer than that in LMHA group and NA group (χ2 = 139.45, P < 0.05).
CONCLUSIONS: The application of RCA in patients with AKI after hepatectomy during CRRT is safe and effective, which can significantly prolong the life of the filter and reduce the risk of bleeding.
参考来源
- Zhang C, Lin T, Zhang J, et al. [Safety and efficacy of regional citrate anticoagulation in continuous renal replacement therapy in the presence of acute kidney injury after hepatectomy]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018. PMID: 30220281. doi:10.3760/cma.j.issn.2095-4352.2018.08.013
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。